Human cryptosporidiosis in immunodeficient patients in France (2015-2017)

Exp Parasitol. 2018 Sep:192:108-112. doi: 10.1016/j.exppara.2018.08.001. Epub 2018 Aug 11.

Abstract

Cryptosporidiosis is a common disease in children and immunodeficient individuals. In 2006, a national network was set up on the surveillance of human cryptosporidiosis in France. Since January 2015, the 41 tertiary care hospitals and the 3 private laboratories of the French National Network on the surveillance of human cryptosporidiosis have been able to declare confirmed cases of cryptosporidiosis online. Between 2015 and 2017, 210 cases of cryptosporidiosis were declared in immunodeficient patients in France; Cryptosporidium parvum and Cryptosporidium hominis represented 66% and 22% of cases, respectively. A peak was observed in autumn. Cryptosporidiosis occurred mainly in a context of solid organ transplantation (SOT) (49%) and of HIV infection (30%). In SOT recipients, cryptosporidiosis appeared more frequently in the first 6 months post transplantation. Regarding cases declared in SOT recipients, mycophenolate mofetil was used in 68%. A mortality rate of 6% was observed. Present results underline the importance of screening for cryptosporidiosis in immunocompromised patients suffering from diarrhea, especially in the course of major cell mediated immunodeficiency or even systematic screening before SOT. Exclusive Cryptosporidium free water feeding could be suggested during major cell mediated immunodeficiency.

Keywords: Cryptosporidiosis; Epidemiology; France; Immunocompromised; Protozoan.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Cryptosporidiosis / epidemiology*
  • Cryptosporidiosis / immunology
  • Cyclosporine / adverse effects
  • Cyclosporine / therapeutic use
  • Female
  • France / epidemiology
  • Humans
  • Immunocompromised Host*
  • Immunosuppression Therapy / adverse effects
  • Immunosuppression Therapy / methods
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Immunotherapy / adverse effects*
  • Immunotherapy / methods
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Mycophenolic Acid / adverse effects
  • Mycophenolic Acid / therapeutic use
  • Risk Factors
  • Tacrolimus / adverse effects
  • Tacrolimus / therapeutic use
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Mycophenolic Acid
  • Tacrolimus